Omalizumab treats chronic rhinosinusitis with nasal polyps and asthma together-a real life study

Bidder, Therese; Sahota, Jagdeep; Rennie, C.; Lund, Valerie J.; Robinson, Douglas S.; Kariyawasam, Harsha H.

doi:10.4193/rhin17.139

Cited by 81 publications

(72 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…To date, one study evaluated omalizumab vs sinus surgery in patients with grade 3 CRSwNP and asthma. 49 It was concluded that omalizumab is equally effective in reducing SNOT-22 at 16 weeks to sinus surgery. However, large-scale studies are needed to confirm these findings in order to decide upon whether or not biologics could be a valid alternative to primary sinus surgery.…”

Section: Indic Ations For B Iolog Ic Smentioning

confidence: 99%

“…36,[42][43][44][45][46] A number of trials have been done with biological therapies for CRSwNP. [47][48][49][50] As these drugs enter the market, it necessitates the medical community to reflect on the positioning of these therapies in the current care pathways of the upper and lower airways. 51,52 The European Forum for Research and Education in Allergy…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

EUFOREA consensus on biologics for CRSwNP with or without asthma

Fokkens

Lund

Bachert

et al. 2019

Allergy

294

288

View full text Add to dashboard Cite

This is an open access article under the terms of the Creat ive Commo ns Attri bution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. AbstractNovel therapies such as type 2 targeting biologics are emerging treatment options for patients with chronic inflammatory respiratory diseases, fulfilling the needs of | 2313 FOKKENS Et al.

show abstract

Section: Indic Ations For B Iolog Ic Smentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

EUFOREA consensus on biologics for CRSwNP with or without asthma

Fokkens

Lund

Bachert

et al. 2019

Allergy

294

288

View full text Add to dashboard Cite

show abstract

“…105,106 High numbers of MCs have been described in NPs, and MCs were implicated in shaping a type 2 inflammatory milieu. 107 Anti-IgE was effective in reducing nasal symptoms and NP size in patients with CRS without or with NPs and eosinophilic inflammation, [108][109][110] which is in line with a possible contribution of MCs.…”

Section: Atopic Diseasesmentioning

confidence: 58%

Mast cells drive IgE-mediated disease but might be bystanders in many other inflammatory and neoplastic conditions

Maurer

Taube

Schröder

et al. 2019

Journal of Allergy and Clinical Immunology

View full text Add to dashboard Cite

Mast cells (MCs) are capable of executing powerful inflammatory response programs triggered by surface IgE cross-linking or through pattern recognition receptors. The question of how MCs contribute to human disease has been intensely investigated and stimulated much controversy. Correlative evidence comes from human studies, pointing to pathogenetic or protective MC functions in patients with atopic conditions, autoimmune disorders, type 2 diabetes, chronic urticaria, mastocytosis, and cancer. Experiments in MC-deficient mice underpinned key roles for MCs in patients with IgE-mediated allergic conditions. Important pathogenetic MC contributions to other inflammatory and neoplastic conditions were suggested by studies in traditional KIT mutant MC-deficient mouse strains. However, many of these findings were not reproduced in more recently developed improved mouse models of MC deficiency, largely ruling out roles for MCs in mouse models for autoimmune disease, diabetes, and cancer. We discuss limitations of studies in mice and human subjects and provide suggestions for how they can be overcome, such as through the development of specific and selective MC-targeted treatments. (J Allergy Clin Immunol 2019;144:S19-30.)

show abstract

“…In the last years a number of studies has appeared that show effectiveness of anti-IgE (Omalizumab) (4)(5)(6) , anti-IL-5 (Mepolizumab) (7) and antiIL4Ra (Dupilumab) (8) .…”

mentioning

confidence: 99%

A new year, a new Journal

Fokkens

2018

Rhin

View full text Add to dashboard Cite

Let us start this first editorial of 2018 with wishing you all a marvelous year where most of your dreams come true.In the last years, the editors of Rhinology felt often very unhappy when again we had to refuse papers send to us for Rhinology. Unfortunately, every year we can only accept around 15% of the papers we receive. With pain in our hearts, we often have to refuse papers of good quality but just not innovative enough or with slight methodological imperfections.The editorial board of Rhinology recognized this feeling and we decided to start a new journal: Rhinology Online to have space for all those papers that are good but just do not make the cut for Rhinology. Rhinology Online is a journal of the European Rhinologic Society, and will provide a platform for the dissemination of rhinologic research and reviews, as well as position papers, task force reports and guidelines, amongst an international scientific audience.Rhinology Online is a peer-reviewed, Open Access journal that will accept original research articles, review articles, protocols of clinical studies, letters to the editor, position papers, task force reports and guidelines and case reports in rhinology.Open access publishing enables free access to all content ensuring a wide dissemination of articles; the electronic format and expert peer review allows for very rapid publication. Publications will be available in Pubmed within a week after acceptance.Rhinology Online is an international journal reaching out far beyond the borders of Europe, and invites clinicians and researchers from all countries of the world to contribute.We look forward to have a modern lively journal with a lot of discussion. Please have look at the website: www.rhinologyonline.org and start sending in your papers.In this issue of Rhinology, a number of very interesting papers can be found. Two systematic reviews are presented. One on the effect of intranasal bevacizumab in the treatment of Hereditary haemorrhagic telangiectasia (HHT) -related epistaxis.Bevacizumab is a selective recombinant human antibody against VEGF -A isomers. It has also become first-line treatment for symptomatic hepatic AVMs in HHT, and based on this success, several studies have analysed the effect of bevacizumab on other HHT outcomes including epistaxis (1) . However, despite initial promising results, it remains unclear whether the agent provides any true benefit in epistaxis outcome (1) . Two years ago, the same authors published an excellent overview of all potential treatment options in HHT (2) in which they presented a treatment algorithm based on tamoxifen, followed by/ combined with ktp laser, septodermoplasty and finally nasal closure by the Lund modification of the Young's procedure (3) .The other review is very timely and summarizes the possibilities to treat CRSwNP with monoclonal antibodies. In the last years a number of studies has appeared that show effectiveness of anti-IgE (Omalizumab) (4-6) , anti-IL-5 (Mepolizumab) (7) and antiIL4Ra (Dupilumab) (8) .In CRSwNP our medical trea...

show abstract

Omalizumab treats chronic rhinosinusitis with nasal polyps and asthma together-a real life study

Cited by 81 publications

References 16 publications

EUFOREA consensus on biologics for CRSwNP with or without asthma

EUFOREA consensus on biologics for CRSwNP with or without asthma

Mast cells drive IgE-mediated disease but might be bystanders in many other inflammatory and neoplastic conditions

A new year, a new Journal

Contact Info

Product

Resources

About